オランダ - 英語 - HMA (Heads of Medicines Agencies)

novartis sa - milbemycin a<3>-oxim 12.5 mg, praziquantel 125 mg - chewable tablet - dogs - milbemycin, combinations

ポルトガル - 英語 - HMA (Heads of Medicines Agencies)

novartis sa - milbemycin a<3>-oxim 12.5 mg, praziquantel 125 mg - chewable tablet - dogs - milbemycin, combinations

スロベニア - 英語 - HMA (Heads of Medicines Agencies)

novartis sa - milbemycin a<3>-oxim 12.5 mg, praziquantel 125 mg - chewable tablet - dogs - milbemycin, combinations

イギリス - 英語 - HMA (Heads of Medicines Agencies)

novartis sa - milbemycin a<3>-oxim 12.5 mg, praziquantel 125 mg - chewable tablet - dogs - milbemycin, combinations

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

novartis animal health us, inc. - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

novartis animal health us, inc. - clomipramine hydrochloride (unii: 2lxw0l6gwj) (clomipramine - unii:nuv44l116d) - clomipramine hydrochloride 5 mg

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

novartis animal health us, inc. - lufenuron (unii: 1r754m4918) (lufenuron - unii:1r754m4918) - lufenuron 45 mg

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); valsartan, quantity: 320 mg - tablet, film coated - excipient ingredients: crospovidone; colloidal anhydrous silica; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; iron oxide yellow; titanium dioxide; hypromellose; purified talc; macrogol 4000 - amlodipine/valsartan novartis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 320 mg; hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; crospovidone; microcrystalline cellulose; hypromellose; purified talc; iron oxide yellow; macrogol 4000 - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); hydrochlorothiazide, quantity: 25 mg; valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; crospovidone; microcrystalline cellulose; hypromellose; purified talc; iron oxide yellow; macrogol 4000 - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).